EICHORPublic-registry site landscape for NCT05363605, “A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours”, a Advanced Solid Tumor study sponsored by Fusion Pharmaceuticals Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05363605 (registry record) |
| Study title | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours |
| Official title | A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours |
| Sponsor | Fusion Pharmaceuticals Inc. |
| Condition(s) | Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma; Bladder Carcinoma; Susceptible FGFR3 Genetic Alterations |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 6 |
| Intervention(s) | [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab |
| Site countries | United States, Australia |
Patient-friendly overview of this study: eichor.com/study/NCT05363605.
Eichor generates a preliminary site-risk snapshot for NCT05363605 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
